Fezolinetant

The Annual Meeting of The Menopause Society will have a strong focus on the era of precision medicine in women’s health, especially in the realm of menopause and oncology.

The North American Menopause Society released its 2023 Nonhormone Therapy Position Statement recommending up-to-date scientific evidence for nonhormonal options for managing menopausal symptoms.

BALTIMORE — Treatment with once-daily oral fezolinetant was effective for reducing moderate to severe hot flashes associated with menopause in a diverse population, according to findings reported at the ACOG Annual Clinical & Scientific Meeting.

The FDA announced it has approved fezolinetant for the treatment of moderate to severe hot flashes due to menopause.

Three SKYLIGHT phase 3 trials demonstrated that treatment with nonhormonal fezolinetant was associated with alleviation moderate to severe vasomotor symptoms during menopause with acceptable safety and tolerability.

The nonhormonal selective neurokinin-3 receptor antagonist fezolinetant was effective and well tolerated in treating moderate to severe vasomotor symptoms associated with menopause, according to study data.

Foot massages were found to decrease sleep disturbances, fatigue and anxiety symptoms during menopause, according to a study published in Menopause earlier this year.

The Healio editors have compiled the most read news from the NAMS annual meeting in October.

Women taking fezolinetant for moderate to severe vasomotor symptoms experienced a reduction in symptom severity and sleep disturbances, according to data presented at the NAMS Annual Meeting.

The FDA accepted a new drug application from Astellas for fezolinetant, a nonhormonal drug for treating moderate to severe menopause-related vasomotor symptoms, according to a company press release.